Top Medical News
Both denosumab and bisphosphonates enhance bone mineral density (BMD) in men with nonmetastatic prostate cancer who are receiving androgen deprivation therapy (ADT), according to a systematic review and meta-analysis. In addition, denosumab lowers the risk for radiographic vertebral fractures.
A recent study has shown that patients with panurothelial carcinoma who underwent radical cystectomy and then radical nephroureterectomy with locally advanced disease in a large proportion have poor prognosis.
2 days ago
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Jairia Dela Cruz, 3 days ago
Capecitabine appears to provide additional survival benefit in triple-negative breast cancer patients treated with standard chemotherapy, significantly improving disease-free survival and overall survival but potentially increasing adverse events consistent with the drug’s known toxicity profile, according to a meta-analysis.
3 days ago
Increased white blood cell count and decreased relative lymphocyte count are associated with serious adverse events (AEs) such as grade 3/4 or lung/gastrointestinal immune-related AEs in nivolumab-treated patients with melanoma, a study has found.
5 days ago
Starting radiation therapy (RT) shortly after breast-conserving surgery does not appear to yield improvements in long-term outcome, bringing into question the common position that RT should be initiated as soon as possible following surgery so as to increase treatment efficacy in breast cancer patients, according to a recent study.
Roshini Claire Anthony, 5 days ago

Young women with HER2-negative breast cancer had improved breast cancer-free interval (BCFI) rates following treatment with ovarian function suppression (OFS) in addition to tamoxifen or exemestane, according to a recent study.

Special Reports
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).
Prof. Ignatius Ou Sai Hong, Dr. James Suh, Dr. Wong Seng Weng, Dr. Amit Verma, 14 May 2017
As targeted cancer therapy options are increasing, it is becoming more important to choose the most appropriate treatment for patients with cancer. At a Roche-sponsored symposium held during the 2nd ESMO Asia Congress in Singapore, four experts discussed the potential of comprehensive genomic profiling (CGP) for personalizing cancer care and helping healthcare professionals to make the best treatment decisions for individual patients.
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. Fred Hirsch, 28 Mar 2017
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
14 Mar 2017
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.
31 Jan 2017
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
Yao-Hua Law, PhD, 15 Dec 2016
The genomics of cancer patients affect their responses to therapies. Some genomic alterations in cancer genes are better treated with targeted therapies, and physicians informed by genomic profiles of their patients can better decide on optimal treatments. Next-generation sequencing (NGS) technology has facilitated rapid and inexpensive gene sequencing for clinical use. This article discusses NGS applications for cancer management, focusing on comprehensive genomic profiling (CGP).
Conference Reports
Elaine Tan, 11 Aug 2017

Prostate biopsy using the multiparametric MRI/ultrasound fusion-guided (mpMRI/US) technique improves prostate cancer diagnosis and reduces the detection of clinically insignificant cancers, according to data presented the 15th Urological Association of Asia Congress (UAA 2017) held recently in Hong Kong.

Naomi Rodrig, 10 Aug 2017

Optimizing perioperative chemotherapy in bladder cancer (BC) presents a clinical challenge, as reflected in a debate at the 15th Urological Association of Asia Congress held in Hong Kong, which focused on the benefits and drawbacks of adjuvant chemotherapy (AC) after radical cystectomy (RC).

Naomi Rodrig, 10 Aug 2017

Practice-changing results from several clinical trials reported in the past 2 years have offered new effective treatment options for hormone-naïve prostate cancer (PC) patients, according to Dr Gerhardt Attard from the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, who spoke at the 15th Urological Association of Asia Congress (UAA 2017) held recently in Hong Kong.

Dr. Joseph Delano Fule Robles, 10 Aug 2017

Chemotherapy has shown dismal results in treatment of metastatic urothelial cancer (UC). The advent of immunotherapy in UC has improved responses and overall survival (OS) in both chemotherapy-pretreated and treatment-naïve patients, according to data presented at the recent 15th Urological Association of Asia Congress held in Hong Kong. 

Christina Lau, 08 Aug 2017

The current protocol for risk stratification of prostate cancer at diagnosis is inaccurate, according to new data from the ProtecT (Prostate Testing for Cancer and Treatment) trial presented at the 15th Urological Association of Asia Congress (UAA 2017) held recently in Hong Kong.

Dr. Joseph Delano Fule Robles, 24 Jul 2017

Recent results of a phase II trial showed favourable responses to dasatinib in patients with imatinib-resistant/intolerant or newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP), according to findings presented at the 22nd Congress of European Hematology Association (EHA 2017) held in Madrid, Spain. 

Christina Lau, 21 Jul 2017

Selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres does not improve overall survival (OS) vs sorafenib in patients with locally advanced hepatocellular carcinoma (HCC), although it significantly improves tumour response and reduces adverse events (AEs), the phase III SARAH study has shown.

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!